ODTC.D Stock Overview
Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Odonate, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15,900.00 |
| 52 Week High | US$49,895.00 |
| 52 Week Low | US$13,625.00 |
| Beta | 0 |
| 1 Month Change | -5.72% |
| 3 Month Change | 15.64% |
| 1 Year Change | -11.67% |
| 3 Year Change | -52.11% |
| 5 Year Change | -93.12% |
| Change since IPO | -93.09% |
Recent News & Updates
Recent updates
Companies Like Odonate Therapeutics (NASDAQ:ODT) Could Be Quite Risky
Nov 18
Companies Like Odonate Therapeutics (NASDAQ:ODT) Could Be Quite Risky
Jun 09Odonate Therapeutics: Lessons Learned
Apr 27We're Keeping An Eye On Odonate Therapeutics' (NASDAQ:ODT) Cash Burn Rate
Mar 09Revisiting Odonate Therapeutics
Feb 01Odonate: A Simple Story Of An Oral Taxane
Jan 10Odonate Therapeutics: Likely Tesetaxel Approval Means Company Is Undervalued
Jan 08Insider Buying: The Odonate Therapeutics, Inc. (NASDAQ:ODT) Independent Director Just Bought US$51k Worth Of Shares
Jan 07Odonate CEO buys $4.2M shares
Dec 24Odonate announces positive Phase 3 data in metastatic breast cancer
Dec 11Is Odonate Therapeutics (NASDAQ:ODT) In A Good Position To Invest In Growth?
Dec 09
Odonate Therapeutics EPS in-line
Oct 28Shareholder Returns
| ODTC.D | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 2.9% | -2.3% | -3.7% |
| 1Y | -11.7% | 11.4% | 20.2% |
Return vs Industry: ODTC.D underperformed the US Pharmaceuticals industry which returned 11.7% over the past year.
Return vs Market: ODTC.D underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| ODTC.D volatility | |
|---|---|
| ODTC.D Average Weekly Movement | 13.4% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ODTC.D's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine ODTC.D's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | n/a | Kevin Tang | www.odonate.com |
Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023.
Odonate, Inc. Fundamentals Summary
| ODTC.D fundamental statistics | |
|---|---|
| Market cap | US$45.16m |
| Earnings (TTM) | -US$102.07m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs ODTC.D overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ODTC.D income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$102.07m |
| Earnings | -US$102.07m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did ODTC.D perform over the long term?
See historical performance and comparison